← Leaderboards
Max Jan
Massachusetts General Hospital
$1,188,918
Attributed
$1,188,918
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $321.1K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,188,918 · 2
By mechanism
K08$951,066 · 1
OT2$237,852 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Marcela Valderrama Maus$16,508,365
- Gian Paolo Dotto$22,106,352
- Rakesh K. Jain$48,476,214
- Engin Deniz$2,753,104
- Kristopher Kahle$4,520,985
Others in their field
Other Emerging Leaders on “Solid”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Hanjoon Ryu$28,519,898
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$24,099,336
- Crystal Mackall · Children'S Hosp Of Philadelphia$17,065,895
- Bronwen Shaw · Medical College Of Wisconsin$10,707,191
Research focus
SolidResearch PersonnelMemoryMediatingProgramsProteinsFunctional DisorderImmuneLenalidomideMassachusettsMolecularPharmaceutical PreparationsDesignProtein DegradationChimeric Antigen Receptor T CellsEngineeringGluesGenesIn VivoCell PhysiologyCellsMalignant NeoplasmsCellular ImmunotherapySolid Neoplasm
Grant awards (7)
Reprogramming the chimeric antigen receptor T cell epigenome to augment anti-tumor activity$188,676
K08 · FY2025 · CA · contact PI
PROTECT - Harnessing Protein Degradation for Advancing Childhood Tumors$132,463
OT2 · FY2025 · CA · contact PI
Reprogramming the chimeric antigen receptor T cell epigenome to augment anti-tumor activity$188,676
K08 · FY2024 · CA · contact PI
PROTECT - Harnessing Protein Degradation for Advancing Childhood Tumors$105,389
OT2 · FY2024 · CA · contact PI
Reprogramming the chimeric antigen receptor T cell epigenome to augment anti-tumor activity$189,438
K08 · FY2023 · CA · contact PI
Reprogramming the chimeric antigen receptor T cell epigenome to augment anti-tumor activity$192,138
K08 · FY2022 · CA · contact PI
Reprogramming the chimeric antigen receptor T cell epigenome to augment anti-tumor activity$192,138
K08 · FY2021 · CA · contact PI